Characterization CYP1A2, CYP2C9, CYP2C19 and CYP2D6 polymorphisms using HRMA in Psychiatry patients with schizophrenia and bipolar disease for personalized medicine.

CONCLUSION: The knowledge in pharmacogenomics and also the developments in molecular genetics are growing rapidly. In the future this can be expected to provide new methodologies in the prediction of the activity in drug metabolizing enzymes. The HRMA is a rapid and useful technique to identify the genotypes for drug dosage adjustment before therapy in psychiatry patients. PMID: 29921201 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/29921201?dopt=Abstract

Source: Combinatorial Chemistry and High Throughput Screening - June 19, 2018 Category: Chemistry Authors: Yenilmez ED, Tamam L, Karaytug O, Tuli A Tags: Comb Chem High Throughput Screen Source Type: research